Wilson Therapeutics AB Kungsgatan 3 | 111 43 Stockholm | Sweden +46 8 796 00 00 www.wilsontherapeutics.com 1 • • • • • • • • • • • • • • • Jonas Hansson, CEO of Wilson Therapeutics Amounts in SEK 000s Jul–Sep Jan–Sep Jan–Dec 2017 2016 2017 2016 2016 1) Adjusted for share split 1:10 resolved in April 2016.

alxninvestorslides ® Alexion to Acquire Wilson Therapeutics Conference Call AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a

Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients. Budpremien är 70 procent jämfört med stängningskursen för Wilson Therapeutics-aktien om 136 kronor den 10 april, vilket alltså är den sista handelsdagen före offentliggörandet av budet. Budet motsvarar en premie om 89 procent jämfört med den volymviktade genomsnittliga kursen för Wilson Therapeutics-aktien under de senaste 90 handelsdagarna fram till och med den 10 april 2018. Wilson is committed to achieving Level AA conformance with the Web Content Accessibility Guidelines (WCAG) 2.0 and achieving compliance with other accessibility standards. Please contact Customer Service at 1-800-401-7967, if you have any issues accessing information on this website.

Wilson therapeutics website

Printed copies can be ordered by post to Wilson Therapeutics AB (publ), Kungsgatan 3, SE-111 43 Stockholm, Sweden, by telephone +46 (0) 8 796 00 00 or by e-mail 2021-04-06 The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website. ABOUT WILSON THERAPEUTICS Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Apr 27, 2018 As of today, the 2017 Annual Report of Wilson Therapeutics AB (publ) is available as a pdf file on the company’s website www.wilsontherapeutics.com. Printed copies can be ordered by post to Wilson Therapeutics AB (publ), Kungsgatan 3, SE-111 43 Stockholm, Sweden, by telephone +46 (0) 8 796 00 00 or by e-mail to lisa.andersson@wtx.se. … Read more Wilson Therapeutics AB is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ product, WTX101, is in Phase 3 development as a novel treatment for Wilson disease.

SEC Filing | Alexion Pharmaceuticals, 19 Apr 2017 Wilson Therapeutics' 2016 Annual Report Published - read this article as a pdf file on the company's website www.wilsontherapeutics.com.

Clinical Development and Medical Sciences at Alexion Pharmaceuticals. business acquisitions of Syntimmune, and Wilson Therapeutics, collaborative

Wilson Therapeutics AB 556893-0357 (Stockholm) Översikt Telefonnummer Adresser Styrelse och koncern Verklig huvudman Nyckeltal Kreditupplysning Wilson Therapeutics börjar handlas på Nasdaq Stockholm den 12 maj 2016. Erbjudandet i samband med noteringen är en nyemission på 380 Mkr som kan utökas med 37,4 Mkr, samt att en övertilldelningsoption 62,6 Mkr kan användas.

"Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson's disease through development of new treatment options and support for increased awareness and education about Wilson's disease.

Det offentliga uppköpserbjudandet från Alexion Pharmaceuticals, Inc. genom Alexion Pharma Nordics Holding AB Wilson Therapeutics AB Kungsgatan 3 | 111 43 Stockholm | Sweden +46 8 796 00 00 www.wilsontherapeutics.com 1 • • • • • • • • • • • • • • • Jonas Hansson, CEO of Wilson Therapeutics Amounts in SEK 000s Jul–Sep Jan–Sep Jan–Dec 2017 2016 2017 2016 2016 1) Adjusted for share split 1:10 resolved in April 2016. Publication date Issuer Person discharging managerial responsibilities Position Closely associated Nature of transaction Instrument name ISIN Transaction date 17 Jan 2018 ? Wilson Therapeutics is enrolling patients in Phase 3 trials of its lead product, WTX101, for Wilson disease and intends to file for regulatory Wilson Therapeutics CMD 2018. This website uses cookies to ensure you get the best experience on this website. Cookies policy. DeclineAccept 11 Apr 2018 Alexion Pharmaceuticals plans to shell out $855 million to acquire Wilson Therapeutics, the companies said today, in a deal that would add its Introduction: Wilson disease (WD) is a genetic disorder in which excess toxic providing medical writing support which was funded by Wilson Therapeutics AB. This website uses cookies to ensure you get the best experience on our website. Learn more.

Titta gärna in om ett par dagar igen, så får du se alla nyheter! Wilson Therapeutics.
Plasil medicine

ABOUT WILSON As of today, the 2017 Annual Report of Wilson Therapeutics AB (publ) is available as a pdf file on the company's website As of today, the 2016 Annual Report of Wilson Therapeutics AB (publ) is available as a pdf file on the company's website www.wilsontherapeutics.com. höjs - HD TA Nytt. Media/News Company. Financial Service.

2018 Alexion Pharmaceuticals, Inc., ett bolag med säte i Delaware, USA, vars aktier är noterade på NASDAQ med handelssymbol “ALXN” i USA (“Alexion”), har den 11 april, genom Alexion Pharma Nordics Holding AB, via ett pressmeddelande lämnat ett offentligt uppköpserbjudande till aktieägarna i Wilson Therapeutics att Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson's disease through development of new treatment options and support for increased awareness and education about Wilson's disease. Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients. Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals 11th April 2018.
Hvor mye skatt skal jeg betale

företagskort engelska
skrivet i sten
vilket cancerframkallande ämne härrör från bensin
apple kontaktnummer deutschland
bioteknik lth antagning

Wilson Therapeutics NOTERA: Dessa sidor är för närvarande under uppbyggnad, och kommer inom kort innehålla mycket mer information om Wilson Therapeutics: bolagsinformation, aktiegraf, nyckeldata, rapporter m.m. Titta gärna in om ett par dagar igen, så får du se alla nyheter!

Wilson Therapeutics LLC, Latonia, Covington. 318 likes · 35 were here. Online Personal Wellness Sessions At Wilson Massage we really do listen.